IXICO PLC (LSE:IXI, OTC:PHYOF) has secured two new contracts worth around £1.3 million to provide neuroimaging services for clinical trials in Alzheimer’s disease and Friedreich’s ataxia.
The AIM-listed neuroscience company, known for its artificial intelligence-powered imaging and biomarker analysis, will support a phase I Alzheimer’s trial for a major pharmaceutical firm.
This contract will run for about three and a half years and involves trial management and imaging analysis.
Separately, IXICO has signed a six-year deal with a US biotech company to assist with imaging data collection for a phase Ib trial focused on Friedreich’s ataxia.
This rare inherited disorder progressively damages the nervous system and heart, making accurate imaging crucial for surgical planning.
"The contract wins underline the innovative, adaptable and agile nature of the IXICO platform and our teams as irrefutable thought leaders in the neurodegenerative disease space," said CEO Bram Goorden.
"The two deals hit different key elements of our strategy, respectively supporting Alzheimer's as a core indication, and maintaining our leadership position in the rare CNS disease space."